Bladder cancer is treatable, and the majority of people diagnosed with it survive. When caught before it spreads beyond the bladder, the five-year survival rate is 73%. Even cancers that have reached nearby lymph nodes have a five-year survival rate of about 42%. The outlook depends heavily on how early the cancer is found and how deeply it has grown into the bladder wall.
About a third of bladder cancers are diagnosed while still confined to the bladder lining, which is the most treatable stage. Treatment options range from minor outpatient procedures to major surgery, with newer drug combinations continuing to improve outcomes for more advanced cases.
Non-Muscle-Invasive: The Most Common Type
Roughly 70% to 80% of bladder cancers are caught at a stage where they haven’t grown into the muscle layer of the bladder wall. These are called non-muscle-invasive, and treatment typically starts with a procedure called transurethral resection. A surgeon passes a thin instrument through the urethra and shaves or scrapes the tumor off the bladder lining. There’s no external incision, and most people go home the same day or the next.
After removal, many patients receive a treatment delivered directly into the bladder through a catheter. The most common version uses a weakened form of a tuberculosis bacterium (BCG) that triggers the immune system to attack any remaining cancer cells. In studies of high-risk patients, three-year disease-free survival after BCG treatment was about 66%, and the rate of the cancer progressing to a more dangerous stage was only around 13%. These numbers make BCG one of the oldest and most effective immunotherapies in cancer medicine.
The catch with non-muscle-invasive bladder cancer is that it frequently comes back. That’s why follow-up monitoring is a central part of treatment, not just an afterthought.
Muscle-Invasive: When Surgery Is the Standard
When cancer has grown into the muscle wall of the bladder, the standard approach for a cure combines chemotherapy followed by surgical removal of the entire bladder, a procedure called radical cystectomy. Chemotherapy given before surgery shrinks the tumor, which makes it easier to remove completely and treats any microscopic cancer cells that may have already spread.
Radical cystectomy is a major operation. In men, it involves removing the bladder, prostate, and surrounding tissues. In women, it includes the bladder, uterus, ovaries, and part of the vaginal wall. The surgeon also creates a new way for urine to leave the body, either through an external bag or by constructing an internal reservoir from a section of intestine. At experienced surgical centers, the risk of dying from the operation itself is 2% to 3%.
Even with successful surgery, there’s roughly a 30% to 40% chance of the cancer returning. That’s why pre-surgical chemotherapy is so important: it gives patients the best shot at long-term survival by attacking the disease on two fronts.
Robotic vs. Open Surgery
Many centers now offer robotic-assisted cystectomy alongside the traditional open approach. A meta-analysis of eight randomized trials covering over 1,000 patients found that robotic surgery resulted in less blood loss (about 322 ml less on average), fewer blood transfusions, a shorter hospital stay, and lower rates of blood clots. Open surgery was faster in the operating room by roughly 76 minutes. Importantly, cancer outcomes were equivalent: no differences in survival, margin clearness, or the number of lymph nodes removed. Robotic surgery also showed better scores for physical functioning and daily activity during recovery.
A New Option for Patients Who Can’t Tolerate Chemo
Not everyone with muscle-invasive bladder cancer can handle the standard chemotherapy regimen, which is built around a drug called cisplatin. Kidney problems, hearing loss, heart conditions, and overall frailty can make cisplatin too risky. For years, these patients had fewer options.
In late 2025, the FDA approved a combination of two newer drugs for use before and after bladder removal surgery in patients who are ineligible for cisplatin. The combination pairs an immune checkpoint inhibitor with an antibody-drug conjugate, a type of targeted therapy that delivers a cell-killing payload directly to cancer cells. In the clinical trial of 344 patients, those who received the new combination before and after surgery had dramatically better outcomes. Median event-free survival had not yet been reached in the treatment group, compared to 15.7 months with surgery alone, and the risk of disease progression or death was cut by 60%.
Metastatic Bladder Cancer: Harder but Not Hopeless
When bladder cancer has spread to distant organs, the five-year survival rate drops to about 10%. That’s a difficult number, but it doesn’t tell the whole story. Immunotherapy drugs called checkpoint inhibitors have changed the landscape for metastatic bladder cancer over the past several years.
In a study of patients treated with checkpoint inhibitors, about 10% achieved a complete response, meaning no detectable cancer remained. Another 23% had a partial response, with significant tumor shrinkage. For those who achieved a complete response, the five-year survival rate was 73%, and the median duration of that response was nearly 52 months (over four years). Even partial responders had a median response duration of about 21 months. These are meaningful stretches of time that didn’t exist with older chemotherapy-only approaches.
The challenge is that roughly half of metastatic patients don’t respond to immunotherapy at all. Ongoing efforts focus on identifying which patients are most likely to benefit and developing new drug combinations to improve those odds.
What Follow-Up Looks Like
Bladder cancer has one of the highest recurrence rates of any cancer, which means monitoring continues for years after treatment. The first check, a cystoscopy (a thin camera passed into the bladder), happens three months after the initial tumor removal. That first follow-up is considered one of the most important predictors of how the disease will behave going forward.
After that, the schedule depends on how aggressive the original cancer was:
- Low-risk tumors: Cystoscopy at 3 and 12 months, then annually for five years total.
- Intermediate-risk tumors: Cystoscopy at 3 months, then every six months for two years, then annually for up to ten years.
- High-risk tumors: Cystoscopy every three months for two years, every six months until year five, then annually for life. These patients also get annual CT imaging of the urinary tract.
This surveillance schedule is demanding, especially for high-risk patients. But catching a recurrence early, when it’s still superficial, keeps treatment options wide open and survival rates high.
Factors That Affect Your Outlook
Stage at diagnosis is the single biggest factor in how treatable bladder cancer is. Cancers caught while still in the bladder lining have the widest range of treatment options and the best survival numbers. Cancers that have invaded the muscle layer are still curable for the majority of patients but require more aggressive treatment. Metastatic disease is the most difficult to treat, though immunotherapy has extended survival for a meaningful subset of patients.
Beyond stage, other factors play a role. The grade of the cancer cells (how abnormal they look under a microscope) influences recurrence risk and treatment intensity. Your overall health and kidney function determine which chemotherapy options are available. Smoking is the leading risk factor for developing bladder cancer in the first place, and quitting after diagnosis is strongly encouraged because continued smoking is linked to worse outcomes and higher recurrence rates.
Bladder cancer treatment has more options today than at any point in the past, particularly for patients who previously fell through the gaps of standard chemotherapy regimens. The combination of earlier detection, refined surgical techniques, and newer immunotherapy and targeted drug approaches means that most people diagnosed with bladder cancer have a treatable disease.